Cryptosporidium infection of human intestinal epithelial cells increases expression of osteoprotegerin: A novel mechanism for evasion of host defenses

Journal of Infectious Diseases

Volumn 197, Issue 6, 2008, Pages 916-923

  Castellanos Gonzalez, Alejandro ^a,c   Yancey, Linda S ^a   Wang, Heuy Ching ^a,b   Pantenburg, Birte ^a,c   Liscum, Kathleen R ^a   Lewis, Dorothy E ^a   White Jr , A Clinton ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b USAF   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM HOMINIS; CRYPTOSPORIDIUM MELEAGRIDIS; CRYPTOSPORIDIUM PARVUM; EXPLANT; GENE EXPRESSION; GENETIC REGULATION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; ILEUM MUCOSA; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; JEJUNUM BIOPSY; MICROARRAY ANALYSIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; UPREGULATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; HOST-PARASITE INTERACTIONS; HUMANS; INTESTINAL MUCOSA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPROTEGERIN; SUS SCROFA; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 40949124848     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/528374     Document Type: Article

References (35)

1. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197-204.
2. White AC Jr. Cryptosporidiosis (Cryptosporidium hominis, Cryptosporidium parvum, other species). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:3215-28.
3. Brantley RK, Williams KR, Silva TM, et al. AIDS-associated diarrhea and wasting in northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis 2003; 7:16-22.
4. Flanigan TP, Whalen C, Turner J, et al. Cryptosporidium infection and CD4 count. Ann Intern Med 1992; 116:840-2.
5. Blanshard C, Jackson A, Shanson D, Francos N, Gazzard B. Cryptosporidiosis in HIV-seropositive patients. Q J Med 1992; 85:813-23.
6. Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL, White AC Jr. Cryptosporidiosis in Houston, Texas: a report of 95 cases. Medicine (Baltimore) 1997; 76:118-39.
7. Theodos CM, Sullivan KL, Griffiths JK, Tzipori S. Profiles of healing and nonhealing Cryptosporidium parvum infection in C57Bl/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection. Infect Immun 1997; 65:4761-9.
8. Mead JR, You X. Susceptibility differences to Cryptosporidium parvum infection in two strains of gamma interferon knockout mice. J Parasitol 1998; 84:1045-8.
9. White AC, Robinson P, Okhuysen PC, et al. Interferon-γ expression in jejunal biopsies in experimental human cryptosporidiosis correlates with prior sensitization and control of oocyst excretion. J Infect Dis 2000; 181:701-9.
10. Lumadue JA, Manabe YC, Moore RD, Belitsos PC, Sears CL, Clark DP. A clinicopathologic analysis of AIDS-related cryptosporidiosis. AIDS 1998; 12:2459-66.
11. Chen XM, Levine SA, Tietz P, et al. Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology 1998; 28:906-13.
12. McCole DF, Eckmann L, Laurent F, Kagnoff MF. Intestinal epithelial cell apoptosis following Cryptosporidium parvum infection. Infect Immun 2000; 68:1710-3.
13. Mele R, Gomez Morales MA, Tosini F, Pozio E. Cryptosporidium parvum at different developmental stages modulates host cell apoptosis in vitro. Infect Immun 2004; 72:6061-7.
14. Deng M, Lancto CA, Abrahamsen MS. Cryptosporidium parvum regulation of human epithelial cell gene expression. Int J Parasitol 2004; 34:73-82.
15. Deng M, Rutherford MS, Abrahamsen MS. Host intestinal epithelial response to Cryptosporidium parvum. Adv Drug Deliv Rev 2004; 56:869-84.
16. Elliot DA, Clark DP. Host cell fate on Cryptosporidium parvum egress from MDCK cells. Infect Immun 2003; 71:5422-62.
17. Widmer G, Corey EA, Stein B, Griffiths JK, Tzipori S. Host cell apoptosis impairs Cryptosporidium parvum development in vitro. J Parasitol 2000; 86:922-8.
18. Ojcius DM, Perfettini JL, Bonnin A, Laurent F. Caspase-dependent apoptosis during infection with Cryptosporidium parvum. Microbes Infect 1999; 1:1163-8.
19. Hijjawi NS, Meloni BP, Morgan UM, Thompson RC. Complete development and long-term maintenance of Cryptosporidium parvum human and cattle genotypes in cell culture. Int J Parasitol 2001; 31:1048-55.
20. Dann SM, Wang HC, Gambarin KJ, et al. IL-15 activates human NK cells to clear the intestinal protozoan Cryptosporidium. J Infect Dis 2005; 192:1294-1302.
21. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31:e15.
22. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19:185-93.
23. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249-64.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc, series B 1995; 57:289-300.
25. Pfaffl MW. A new mathematical model for relative quantitation in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
26. Cai X, Woods KM, Upton SJ, Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob Agents Chemother 2005; 49:4437-42.
27. Feng H, Nie W, Sheoran A, Zhang Q, Tzipori S. Bile acids enhance invasiveness of Cryptosporidium spp. into cultured cells. Infect Immun 2006; 74:3342-6.
28. Vidal K, Serrant P, Schlosser B, van den Broek P, Lorget F, Donnet-Hughes A. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol 2004; 287:G836-44.
29. Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138:491-8.
30. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-87.
31. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res 2005; 25:3809-16.
32. Toruner M, Fernandez-Zapico M, Sha JJ, Pham L, Urrutia R, Egan LJ. Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1. J Biol Chem 2006; 281:8686-96.
33. Begue B, Wajant H, Bambou JC, et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006; 130:1962-74.
34. Padigel UM, Kim N, Choi Y, Farrell JP. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. J Immunol 2003; 171:5437-41.
35. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003; 19:849-61.